glpg-0555
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2009 (NCT01023321)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tyrosine-protein kinase JAK1INHIBITOR
JAK1 inhibitor
Backup to GSK-2586184 (GLPG-0778)
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545249 ↗
Also known as
- glpg0555
- glpg-0555
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01278095 | Phase 1 | Jan 1, 2011 | Galapagos NV, SGS Life Sciences |
| NCT01208753 | Phase 1 | Sep 1, 2010 | Galapagos NV, SGS Life Sciences |
| NCT01023321 | Phase 1 | Dec 1, 2009 | Galapagos NV, SGS Life Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galapagos NV | For profit | 3 | 3 | 1 | 2009 |
| SGS Life Sciences | For profit | 3 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1